Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

500 mg bid, or ibuprofen 600 mg tid. At week 13, naproxcinod 750 mg bid showed a reduction in SBP of 2.7 mmHg compared to naproxen 500 mg bid and naproxcinod 375 mg bid showed a reduction in SBP of 1.1 mmHg compared to naproxen 250 mg bid. NicOx believes that the 112 trial is a key study for characterizing the blood pressure profile of naproxcinod, as it used the gold standard ABPM technique to provide data at 13 weeks, in OA patients with hypertension.

Further analyses on the 111 and 112 studies will form the basis of presentations at leading medical conferences and peer reviewed scientific publications during 2009 and 2010.

Interactions with clinical and scientific advisors

In 2008, NicOx organized 11 Advisory Boards to discuss naproxcinod's clinical results with world-famous experts in the fields of rheumatology, cardiology, nephrology and gastroenterology. Clinical advisors were consulted about various topics such as cardiovascular and blood pressure concerns related to traditional NSAIDs and COX-2 inhibitors, blood pressure and gastrointestinal results observed with naproxcinod and nitric oxide's mechanism of action.

The Company also attended 9 scientific congresses in 2008 and sponsored 3 symposia: at the American Heart Association (AHA) annual meeting in New Orleans, the European League Against Rheumatism (EULAR) annual meeting in Paris, and the Osteoarthritis Research Society International (OARSI) congress in Rome. All these events gave NicOx' scientists and clinicians the opportunity to seek advice regarding naproxcinod data from many leading advisors.

Initiation of a series of phase 1b studies by Merck & Co., Inc. in the hypertension field

In May 2008, Merck initiated a series of clinical studies in volunteers with mild to moderate hypertension. This program is part of the March 2006 agreement to develop n
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by product ... Table-top Counters) by End-user (Inpatient Pharmacy Automation, Outpatient ... 2019” analyzes and studies the major market drivers, ... and the Rest of the World (RoW). , ... through 300 pages and in-depth TOC on "Pharmacy ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Conn., Aug. 25, 2011 Advanced BioHealing, ... medicine therapies, today announced that it ranked in the ... list of America,s fastest-growing, privately held companies. ... at a vital segment of the U.S. economy—America,s independent-minded ...
... major impact on future nanoscale device design, such as ... size, many materials like silicon are as brittle as ... compressed into half their size without breaking them. The ... led by Professor Roman Nowak. Atom by atom, ...
... Aug. 24, 2011 Bacterin International Holdings, Inc. ... development of revolutionary bone graft material and antimicrobial coatings for ... Nicolaus 2011 Healthcare Conference. The conference will be held at ... 2011. Bacterin,s chairman and CEO, Guy Cook, and ...
Cached Biology Technology:Advanced BioHealing Named to Prestigious Inc. 500 List of America's Fastest Growing Private Companies 2Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011 2
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... causes those painful lip blisters known as cold sores has an ... it to literally blast its infectious DNA into human cells, scientists ... mechanism the first in a human virus opens the ... study in the Journal of the American Chemical Society . ...
... revealed new images which provide the clearest picture yet ... and tumours. , They show how the cells, which ... human body, change the organisation of their surface molecules, ... viral-infected or tumour cells., Professor Daniel Davis, who has ...
... HUNTSVILLE, Ala -- Even in the absence of a ... and intellectual challenges is helpful to physicians and families. ... high throughput genomic sequencing to meet major diagnostic needs ... totaling more than $7.6 million from the National Institutes ...
Cached Biology News:Researchers reveal the clearest new pictures of immune cells 2HudsonAlpha awarded grant to improve diagnoses of childhood genetic disorders 2
... Bio-Beads SM-2 adsorbents are macroporous polystyrene beads ... high surface area for adsorbing organics of ... solutions. The beads are useful for the ... agents; for example, the removal of detergents ...
... Immunogen : Fusion protein corresponding ... of human Mi-2 Formulation: 0.7M ... 0.035% sodium azide, containing 30% ... by immunoblot on Hela nuclear ...
... Anti-MAPKAPK-2, Phospho-Specific(Thr ... In 150 mM NaCl, 10 ... BSA, 50% glycerol, pH 7.5. ... kinase-activated protein kinase 2 (MAPKAPK-2) ...
...
Biology Products: